NMN vs NR: which precursor and why

NMN versus NR is the question the NAD+ supplement industry argues about most, and the marketing on both sides runs well ahead of the evidence. This post lays out how the two precursors actually relate and why the choice matters less than the noise suggests. It is editorial commentary. We do not sell NMN or NR.

How the two molecules relate

NMN and NR are both precursors the body converts into NAD+, the co-enzyme covered in full on the NAD+ landscape page. They are not rivals in the way the marketing frames them: in the NAD+ salvage pathway, NR can be converted into NMN, which is then converted into NAD+. So the two sit on the same route to the same end-product, a step apart.

That biochemical closeness is the first reason to be sceptical of strong claims that one is decisively superior. Both feed the same pathway, both raise NAD+ markers in humans, and the differences argued over are smaller than the category’s volume of debate implies. For the individual profiles, see the NMN sub-hub and the nicotinamide riboside post.

What the human evidence shows

The human evidence for both precursors points the same way. Studies suggest both NMN and NR reliably raise blood NAD+ markers and are generally well tolerated over the periods studied, which are mostly weeks to a few months. The trials are small, report biomarker shifts rather than clinically meaningful outcomes, and there are no large long-term randomised trials confirming the longevity claims for either.

Crucially, there is limited high-quality head-to-head human evidence directly comparing the two on outcomes that matter. Much of the “NMN is better” or “NR is better” content rests on mechanistic arguments, animal data, or absorption studies rather than on human trials showing one produces better results. That is a thin basis for a confident verdict, and we do not offer one.

Where the real differences lie

The differences that are real are less about effectiveness and more about regulation and availability. NR reached UK shelves earlier and has the more settled regulatory and retail history, as the nicotinamide riboside post describes. NMN went through the turbulent 2022 to 2025 back-and-forth set out in the NMN regulatory status post before stabilising as a UK food supplement.

For a shopper, that translates into NR having had steadier availability over the longest period, while NMN availability is currently broad but has wobbled. Price and form also differ between products more than between the molecules themselves, a point the NMN cost post develops. None of these are reasons to expect a meaningfully different health outcome.

How to actually choose

If you have decided to try a precursor at all, the sensible basis for choosing between NMN and NR is the practical one: a reputable brand, a clear per-capsule milligram count, stated purity or batch testing, and a price you are comfortable with. The NMN label-reading post covers what those signals look like, and they apply equally to NR products.

What is not a sensible basis is a marketing claim that one molecule decisively beats the other on results, because the human evidence does not support that. And the prior question, whether to take a precursor at all, is one for a healthcare professional, especially if you take medication or manage a health condition. Both remain food supplements, not medicines, and neither is a substitute for medical care.